Prostate cancer metastases to bone: pathophysiology, pain management, and the promise of targeted therapy.
暂无分享,去创建一个
[1] M. Rogers,et al. Overview of bisphosphonates , 1997, Cancer.
[2] S. Rabbani,et al. Urokinase overproduction results in increased skeletal metastasis by prostate cancer cells in vivo. , 1994, Cancer research.
[3] R. Coleman. Skeletal complications of malignancy , 1997, Cancer.
[4] D. Fairclough,et al. Magnetic resonance imaging of disseminated bone marrow disease in patients treated for malignancy , 2004, Skeletal Radiology.
[5] C. Tangen,et al. SWOG 99-16: Randomized phase III trial of docetaxel (D)/estramustine (E) versus mitoxantrone(M)/prednisone(p) in men with androgen-independent prostate cancer (AIPCA). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[6] J. Yarnold,et al. Prospective randomised trial of single and multifraction radiotherapy schedules in the treatment of painful bony metastases. , 1986, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[7] F. Saad,et al. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. , 2004, Journal of the National Cancer Institute.
[8] P. Delmas,et al. Bisphosphonates inhibit prostate and breast carcinoma cell adhesion to unmineralized and mineralized bone extracellular matrices. , 1997, Cancer research.
[9] Mundy,et al. Bisphosphonates as anticancer drugs. , 1998, Expert opinion on investigational drugs.
[10] G. Roodman. Mechanisms of bone metastasis. , 2004, Discovery medicine.
[11] L. Collette,et al. Strontium(89) chloride versus palliative local field radiotherapy in patients with hormonal escaped prostate cancer: a phase III study of the European Organisation for Research and Treatment of Cancer, Genitourinary Group. , 2003, European urology.
[12] A. Zwinderman,et al. Effects of the bisphosphonate olpadronate in patients with carcinoma of the prostate metastatic to the skeleton. , 1998, Bone.
[13] L. Matrisian,et al. Matrix metalloproteinases: multifunctional contributors to tumor progression. , 2000, Molecular medicine today.
[14] Leonard,et al. Immunohistochemical localization of parathyroid hormone-related protein in human prostate cancer. , 1993, Cancer Research.
[15] M. Chapuy,et al. Histomorphometric analysis of sclerotic bone metastases from prostatic carcinoma with special reference to osteomalacia , 1983, Cancer.
[16] L. Chung,et al. Androgen-independent cancer progression and bone metastasis in the LNCaP model of human prostate cancer. , 1994, Cancer research.
[17] T. Masaki,et al. The effects of the endothelin family peptides on cultured osteoblastic cells from rat calvariae. , 1990, Biochemical and biophysical research communications.
[18] F. Orr,et al. Pathophysiologic interactions in skeletal metastasis , 2000, Cancer.
[19] R. Wahl,et al. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. , 1996, Radiology.
[20] R. Khokha. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. , 1994, Journal of the National Cancer Institute.
[21] M. Benassi,et al. The responsiveness of bone metastases to radiotherapy: the effect of site, histology and radiation dose on pain relief. , 1989, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.
[22] Bingham Ja. Letter: Lower oesophageal sphincter. , 1974 .
[23] W. Ashburn,et al. Nuclear bone imaging in metastatic cancer of the prostate , 1981, Cancer.
[24] D. Goltzman. Mechanisms of the development of osteoblastic metastases , 1997, Cancer.
[25] Paul J. Williams,et al. Therapeutic efficacy of a soluble receptor activator of nuclear factor kappaB-IgG Fc fusion protein in suppressing bone resorption and hypercalcemia in a model of humoral hypercalcemia of malignancy. , 2001, Cancer research.
[26] J. Nelson,et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[27] R. Pazdur,et al. Approval summary for zoledronic acid for treatment of multiple myeloma and cancer bone metastases. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[28] J. Pinski,et al. Therapeutic implications of enhanced G(0)/G(1) checkpoint control induced by coculture of prostate cancer cells with osteoblasts. , 2001, Cancer research.
[29] J. Pinski,et al. Trk receptor inhibition induces apoptosis of proliferating but not quiescent human osteoblasts. , 2002, Cancer research.
[30] J. Lau,et al. Nonsteroidal anti-inflammatory drugs, alone or combined with opioids, for cancer pain: a systematic review. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] S Paget,et al. THE DISTRIBUTION OF SECONDARY GROWTHS IN CANCER OF THE BREAST. , 1889 .
[32] K. Mohammad,et al. Role of endothelin‐1 in osteoblastic bone metastases , 2003, Cancer.
[33] G. Hortobagyi. Novel approaches to the management of bone metastases. , 2003, Seminars in oncology.
[34] T. Suda,et al. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. , 1990, Journal of immunology.
[35] I. Tannock,et al. Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] P. Kostenuik,et al. Transforming growth factor β upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen , 2004, Clinical & Experimental Metastasis.
[37] M. Klagsbrun,et al. Growth factors in bone matrix. Isolation of multiple types by affinity chromatography on heparin-Sepharose. , 1986, The Journal of biological chemistry.
[38] V. Midy,et al. Vasculotropin/vascular endothelial growth factor induces differentiation in cultured osteoblasts. , 1994, Biochemical and biophysical research communications.
[39] D. Wallwiener,et al. Reduction in new metastases in breast cancer with adjuvant clodronate treatment. , 1998, The New England journal of medicine.
[40] Zuxiong Chen,et al. Prostate specific antigen cleaves parathyroid hormone-related protein in the PTH-like domain: inactivation of PTHrP-stimulated cAMP accumulation in mouse osteoblasts. , 1996, The Journal of urology.
[41] C. Contag,et al. Animal models of bone metastasis , 2003, Cancer.
[42] S. Magnuson,et al. Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer. , 1996, Cancer research.
[43] Shelby D Reed,et al. Cost-effectiveness of zoledronic acid for the prevention of skeletal complications in patients with prostate cancer. , 2004, The Journal of urology.
[44] C. Dinney,et al. Metastatic model for human prostate cancer using orthotopic implantation in nude mice. , 1992, Journal of the National Cancer Institute.
[45] C. Sawyers,et al. Development of an animal model for prostate cancer cell metastasis to adult human bone. , 2001, Anticancer research.
[46] R. Kryscio,et al. A randomized trial of direct decompressive surgical resection in the treatment of spinal cord compression caused by metastasis , 2003 .
[47] E. Ben-Josef,et al. Systemic bone‐seeking radionuclides for palliation of painful osseous metastases: Current concepts , 1998, CA: a cancer journal for clinicians.
[48] A. D'Amico,et al. Prostate cancer : principles and practice , 2002 .
[49] K. Pienta,et al. Pain management in patients with advanced prostate cancer. , 1999, Oncology.
[50] Morris Pollard,et al. Prostate‐seminal vesicle cancers induced in noble rats , 2000, The Prostate.
[51] I. Tannock,et al. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC). , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] G. Mundy. Metastasis: Metastasis to bone: causes, consequences and therapeutic opportunities , 2002, Nature Reviews Cancer.
[53] M. Robson,et al. How is androgen-dependent metastatic prostate cancer best treated? , 1996, Hematology/oncology clinics of North America.
[54] D. Tong,et al. The palliation of symptomatic osseous metastases final results of the study by the radiation therapy oncology group , 1982, Cancer.
[55] B. Fingleton,et al. Matrix Metalloproteinase Inhibitors and Cancer—Trials and Tribulations , 2002, Science.
[56] A. Geldof,et al. Progression delay of prostate tumor skeletal metastasis effects by bisphosphonates. , 1992, The Journal of urology.
[57] I. Ikeda,et al. Pyridinium cross-links as urinary markers of bone metastases in patients with prostate cancer. , 1996, British journal of urology.
[58] P. Sørensen,et al. Metastatic epidural spinal cord compression. Results of treatment and survival , 1990, Cancer.
[59] R. Taichman,et al. Vascular Endothelial Growth Factor Contributes to the Prostate Cancer-Induced Osteoblast Differentiation Mediated by Bone Morphogenetic Protein , 2004, Cancer Research.
[60] D. Rosenthal. Radiologic diagnosis of bone metastases , 1997, Cancer.
[61] V. Devita,et al. Cancer : Principles and Practice of Oncology , 1982 .
[62] J. Turner,et al. A phase I study of samarium-153 ethylenediaminetetramethylene phosphonate therapy for disseminated skeletal metastases. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] R. Payne,et al. Mechanisms and management of bone pain , 1997, Cancer.
[64] G. Sledge,et al. Effect of matrix metalloproteinase inhibitor batimastat on breast cancer regrowth and metastasis in athymic mice. , 1995, Journal of the National Cancer Institute.
[65] G. Oremek,et al. Diagnostic value of bone and tumour markers in patients with malignant diseases. , 2003, Anticancer research.
[66] W. Shipley,et al. Management of spinal cord compression secondary to metastatic prostatic carcinoma. , 1991, The Urologic clinics of North America.
[67] L. Collette,et al. Strontium89 Chloride versus Palliative Local Field Radiotherapy in Patients with Hormonal Escaped Prostate Cancer: A Phase III Study of the European Organisation for Research and Treatment of Cancer Genitourinary Group , 2003 .
[68] M. Kattan,et al. Plasma levels of interleukin-6 and its soluble receptor are associated with prostate cancer progression and metastasis. , 2001, Urology.